Arylamine N-acetyltransferases: Characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2

Chemical Research in Toxicology

Volumn 20, Issue 9, 2007, Pages 1300-1308

  Liu, Li ^a   Von Vett, Annette ^a   Zhang, Naixia ^a   Walters, Kylie J ^a   Wagner, Carston R ^a   Hanna, Patrick E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; ARYLAMINE ACETYLTRANSFERASE 2; DIHYDROFOLATE REDUCTASE; HYBRID PROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BINDING SITE; BIOTRANSFORMATION; BLADDER CANCER; CANCER RISK; CHEMICAL BOND; CHROMATOGRAPHY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SPECIFICITY; GENE OVEREXPRESSION; GENOTOXICITY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; POLLUTANT; STRUCTURE ANALYSIS; WILD TYPE;

ACETYLATION; ANILINE COMPOUNDS; ARYLAMINE N-ACETYLTRANSFERASE; CLONING, MOLECULAR; ENVIRONMENTAL POLLUTANTS; HUMANS; ISOENZYMES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PROTEIN BINDING; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

MAMMALIA; TOBACCO ETCH VIRUS;

EID: 35048820519     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx7001614     Document Type: Article

References (70)

1. Josephy, P. D., and Mannervik, B. (2006) Molecular Toxicology, 2nd ed., pp 426-447, Oxford University Press, New York.
2. Hanna, P. E. (1994) N-Acetyltransferases, O-acetyltransferases and N,O-acetyltransferases: Enzymology and bioactivation. Adv. Pharmacol. 27, 401-430.
3. Hanna, P. E. (1996) Metabolic activation and detoxification of arylamines. Curr. Med. Chem. 3, 195-210.
4. Kim, D., and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol. 45, 27-49.
5. Flammang, T. J., and Kadlubar, F. F. (1986) Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acyltransferases. Carcinogenesis 7, 919-926.
6. Bartsch, H., Dworkin, M., Miller, J. A., and Miller, E. C. (1972) Electrophilic N-acetoxyaminoarenes derived from carcinogenic N-hydroxy-N-acetylaminofluorenes by enzymatic deacetylation and transacetylation in liver. Biochim. Biophys. Acta 286, 272-298.
7. Glowinski, I. B., Weber, W. W., Fysh, J. M., Vaught, J. B., and King, C. M. (1980) Evidence that arylhydroxamic acid N,O-acyltransferase and the genetically polymorphic N-acetyltransferase are properties of the same enzyme in rabbit liver. J. Biol. Chem. 255, 7883-7890.
8. Beland, F. A., and Kadlubar, F. F. (1990) Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. Handb. Exp. Pharmacol. 94/1, 267-325.
9. Grant, D. M., Blum, M., and Meyer, U. A. (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39, 184-191.
10. Minchin, R. F. (1995) Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 307, 1-3.
11. Hein, D. W., Doll, M. A., Rustan, T. D., Gray, K., Feng, Y., Ferguson, R. J., and Grant, D. M. (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14, 1633-1638.
12. Andres, H. H., Vogel, R. S., Tarr, G. E., Johnson, L., and Weber, W. W. (1987) Purification, physicochemical, and kinetic properties of liver acetyl-CoA: Arylamine N-acetyltransferase from rapid acetylator rabbits. Mol. Pharmacol. 31, 446-456.
13. Grant, D. M., Lottspeich, F., and Meyer, U. A. (1989) Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 244, 203-207.
14. Ozawa, S., Abu-Zeid, M., Kawakubo, Y., Toyama, S., Yamazoe, Y., and Kato, R. (1990) Monomorphic and polymorphic isozymes of arylamine N-acetyltransferases in hamster liver: Purification of the isozymes and genetic basis of N-acetylation polymorphism. Carcinogenesis 11, 2137-2144.
15. Cheon, H. G., Boteju, L. W., and Hanna, P. E. (1992) Affinity alkylation of hamster hepatic arylamine N-acetyltransferases: Isolation of a modified cysteine residue. Mol. Pharmacol. 42, 82-83.
16. Trinidad, A., Hein, D. W., Rustan, T. D., Ferguson, R. J., Miller, L. S., Bucher, K. D., Kirlin, W. G., Ogolla, F., and Andrews, A. F. (1990) Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: Identity with polymorphic N-hydroxyarylamine-O-acetyltransferase. Cancer Res. 50, 7942-7949.
17. Mattano, S. S., Land, S., King, C. M., and Weber, W. W. (1989) Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: Identity with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-acetyltransferase. Mol. Pharmacol. 35, 599-609.
18. Ward, A., Sumers, M. J., and Sim, E. (1995) Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem. Pharmacol. 49, 1759-1767.
19. Sticha, K. R. K., Sieg, C. A., Bergstrom, C. P., Hanna, P. E., and Wagner, C. R. (1997) Overexpression and large scale purification of recombinant hamster polymorphic arylamine N-acetyltransferase as a dihydrofolate reductase fusion protein. Protein Expression Purif. 10, 141-153.
20. Sticha, K. R. K., Bergstrom, C. P., Wagner, C. R., and Hanna, P. E. (1998) Characterization of hamster recombinant monomorphic and polymorphic arylamine N-acetyltransferases. Bioactivation and mechanism based inactivation studies with N-hydroxy-2-acetylaminofluorene. Biochem. Pharmacol. 56, 47-59.
21. Wang, H., Vath, G. M., Kawamura, A., Bates, C. A., Sim, E., Hanna, P. E., and Wagner, C. R. (2005) Overexpression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 24, 65-77.
22. Wang, H., Vath, G. M., Gleason, K. J., Hanna, P. E., and Wagner, C. R. (2004) Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady-state kinetic studies. Biochemistry 43, 8234-8246.
23. Wang, H., Liu, L., Hanna, P. E., and Wagner, C. R. (2005) Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 44, 11295-11306.
24. Guo, Z., Wagner, C. R., and Hanna, P. E. (2004) Mass spectrometric investigation of the mechanism of inactivation of hamster arylamine N-acetyltransferase 1 by N-hydroxy-2-acetylaminofluorene. Chem. Res. Toxicol. 17, 275-286.
25. Wang, H., Wagner, C. R., and Hanna, P. E. (2005) Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: A comparison of human and hamster enzymes. Chem. Res. Toxicol. 18, 183-197.
26. Liu, F., Zhang, N., Zhou, X., Hanna, P. E., Wagner, C. R., Koepp, D. M., and Walters, K. J. (2006) Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 361, 482-492.
27. Zhang, N., Liu, L., Liu, F., Wagner, C. R., Hanna, P. E., and Walters, K. J. (2006) NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 363, 188-200.
28. Kawamura, A., Graham, J., Mushtag, A., Tsiftsoglou, S. A., Vath, G. M., Hanna, P. E., Wagner, C. R., and Sim, E. (2005) Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 69, 347-359.
29. NIH Guidelines for the Laboratory Use of Chemical Carcinogens (1981) NIH Publication 81-2385, U.S. Government Printing Office, Washington, DC.
30. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 75, 248-254.
31. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127-134.
32. Gan, J., Skipper, P. L., Gago-Dominquez, M., Arakawa, K., Ross, R. K., Yu, M. C., and Tannenbaum, S. R. (2004) Alkylaniline-hemoglobin adducts and risk of non-smoking related bladder cancer. J. Natl. Cancer Inst. 96, 1425-1431.
33. Palmiotto, G., Pieraccini, G., Moneti, G., and Dolara, P. (2001) Determination of the levels of aromatic amines in indoor and outdoor air in Italy. Chemosphere 43, 355-361.
34. Markowitz, S. B., and Levin, K. (2004) Continued epidemic of bladder cancer in workers exposed to ortho-toluidine in a chemical factory. J. Occup. Environ. Med. 46, 154-160.
35. DeBruin, L. S., Pawliszyn, J. B., and Josephy, P. D. (1999) Detection of monocyclic aromatic amines, possible mammary carcinogens, in human milk. Chem. Res. Toxicol. 12, 78-82.
36. Sinclair, J. C., Delgoda, R., Noble, M. E. M., Jarmin, S., Goh, N. K., and Sim, E. (1998) Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expression Purif. 12, 371-380.
37. Sandy, J., Mushtaq, A., Kawamara, A., Sinclair, J. C., Sim, E., and Noble, M. (2002) The structure of arylamine N-acetyltransferase from Mycobacterium smegamatis: An enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318, 1071-1083.
38. Westwood, I. M., Holten, S. J., Rodrigues-Lima, F., Dupret, J. M., Bhakta, S., Noble, M. E. M., and Sim, E. (2005) Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. 385, 605-612.
39. Talaska, G. (2003) Aromatic amines and human urinary bladder cancer: Exposure sources and epidemiology. J. Environ. Sci. Health C21, 29-43.
40. Talaska, G., and Al-Zoughool, M. (2003) Aromatic amines and biomarkers of human exposure. J. Environ. Sci. Health C21, 133-164.
41. Patrianakos, C., and Hoffman, D. (1979) Chemical studies on tobacco smoke LXIV. On the analysis of aromatic amines in tobacco smoke. J. Anal. Toxicol. 3, 150-154.
42. Bryant, M. S., Vineis, P., Skipper, P. L., and Tannenbaum, S. R. (1988) Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc. Natl. Acad. Sci. U.S.A. 85, 9788-9791.
43. Maclure, M., Katz, R. B.-A., Bryant, M. S., Skipper, P. L., and Tannenbaum, S. R. (1989) Elevated blood levels of carcinogens in passive smokers. Am. J. Public Health 79, 1383-1384.
44. Smith, C. J., Dooly, G. L., and Moldoveanu, S. C. (2003) New technique using solid-phase extraction for the analysis of aromatic amines in mainstream cigarette smoke. J. Chromatogr., A 991, 99-107.
45. Turesky, R. J., Freeman, J. P., Holland, R. D., Nestorick, D. M., Miller, D. W., Ratnasinghe, D. L., and Kadlubar, F. F. (2003) Identification of aminobiphenyl derivatives in commercial hair dyes. Chem. Res. Toxicol. 16, 1162-1173.
46. Bryant, M. S., Simmons, H. F., Harrell, R. E., and Hinson, J. A. (1994) 2,6-Dimethylaniline-hemoglobin adducts from lidocaine in humans. Carcinogenesis 15, 2287-2290.
47. Gaber, K., Harreus, U. A., Matthias, C., Kleinsasser, N. H., and Richter, E. (2007) Hemoglobin adducts of the human bladder carcinogen o-toluidine after treatment with the local anesthetic prilocaine. Toxicology 229, 157-164.
48. Goodfellow, G. H., Dupret, J. M., and Grant, D. M. (2000) Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 348, 159-166.
49. Savulescu, M. R., Mushtaq, A., and Josephy, P. D. (2005) Screening and characterizing human NAT2 variants. Methods Enzymol. 400, 192-215.
50. m. Bioorg. Chem. 30, 211-213.
51. Windmill, K. F., Gaedigk, A., de la M. Hall, P., Samaratunga, H., Grant, D. M., and McManus, M. E. (2000) Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol. Sci. 54, 19-29.
52. Stanley, L. A., Coroneos, E., Cuff, R., Hickman, D., Ward, A., and Sim, E. (1996) Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J. Histochem. Cytochem. 44, 1059-1067.
53. Rodrigues-Lima, F., Cooper, R. N., Goudeau, B., Atmane, N., Chamagne, A.-M., Butler-Browne, G., Sim, E., Vicart, P., and Dupret, J.-M. (2003) Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase. J. Histochem. Cytochem. 51, 784-796.
54. Cribb, A. E., Grant, D. M., Miller, M. A., and Spielberg, S. P. (1991) Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J. Pharmacol. Exp. Ther. 259, 1241-1246.
55. Lawson, T., and Kolar, C. (2002) Human prostate epithelial cells metabolize chemicals of dietary origin to mutagens. Cancer Lett. 175, 141-146.
56. Smelt, V. A., Mardon, H. J., Redman, C. W. G., and Sim, E. (1997) Acetylation of arylamines by the placenta. Eur. J. Drug Metab. Pharmacokinet. 22, 403-408.
57. Derewlany, L. O., Knie, B., and Koren, G. (1994) Arylamine N-acetyltransferase activity of the human placenta. J. Pharmacol. Exp. Ther. 269, 756-760.
58. Kawakubo, Y., Merk, H. F., Al Masoudi, T., Sieben, S., and Blomeke, B. (2000) N-Acetylation of paraphenylenediamine in human skin and keratinocytes. J. Pharmacol. Exp. Ther. 292, 150-155.
59. Dairou, J., Malecaze, F., Dupret, J. M., and Rodrigues-Lima, F. (2005) The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: Inactivation by cellular oxidants and UVB-induced oxidative stress. Mol. Pharmacol. 67, 1299-1306.
60. Geylan, Y. S., Dizbay, S., and Guray, T. (2001) Arylamine N-acetyltransferase activities in human breast cancer tissues. Neoplasma 48, 108-111.
61. Sadrieh, N., Davis, C. D., and Snyderwine, E. G. (1996) N-Acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res. 56, 2683-2687.
62. Williams, J. A., Stone, E. M., Fakis, G., Johnson, N., Cordell, J. A., Meinl, W., Glatt, H., Sim, E., and Philips, D. H. (2001) N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics 11, 373-388.
63. Rodriguez, J. W., Kirlin, W. G., Ferguson, R. J., Doll, M. A., Gray, K., Rustan, T. D., Lee, M. E., Kemp, K., Urso, P., and Hein, D. W. (1993) Human acetylator genotype: Relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch. Toxicol. 67, 445-452.
64. Hickman, D., Pope, J., Patil, S. D., Fakis, G., Smelt, V., Stanley, L. A., Payton, M., Unadkat, J. D., and Sim, E. (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42, 402-409.
65. Hein, D. W. (2006) N-Acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658.
66. Vineis, P., Caporaso, N., Tannenbaum, S. R., Skipper, P. L., Glogowski, J., Bartsch, H., Coda, M., Talaska, G., and Kadlubar, F. (1990) Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res. 50, 3002-3004.
67. Probst-Hensch, N. M., Bell, D. A., Watson, M. A., Skipper, P. L., Tannenbaum, S. R., Chan, K. K., Ross, R. K., and Yu, M. C. (2000) N-Acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol., Biomarkers Prev. 9, 619-623.
68. Sugamori, K. S., Brenneman, D., and Grant, D. M. (2006) In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. Drug Metab. Dispos. 34, 1697-1702.
69. Ronco, G., Vineis, P., Bryant, M. S., Skipper, P. L., and Tannenbaum, S. R. (1990) Hemoglobin adducts formed by aromatic amines in smokers: Sources of inter-individual variability. Br. J. Cancer 61, 534-537.
70. Skipper, P. L., Trudel, L. J., Kensler, T. W., Groopman, J. D., Egner, P. A., Liberman, R. G., Wogan, G. N., and Tannenbaum, S. R. (2006) DNA adduct formation by 2,6-dimethyl-, 3,5-dimethyl-, and 3-ethylaniline in vivo in mice. Chem. Res. Toxicol. 19, 1086-1090.